Genome Editing Stocks List
|ABEO||F||Abeona Therapeutics Inc.||10.53|
|EDIT||F||Editas Medicine, Inc.||1.20|
|NTLA||B||Intellia Therapeutics, Inc.||7.14|
|CRSP||D||CRISPR Therapeutics AG||0.77|
|LOGC||F||LogicBio Therapeutics, Inc.||1.20|
|DTIL||D||Precision BioSciences, Inc.||0.44|
|GNOM||D||Global X Genomics & Biotechnology ETF||10.88|
|HELX||D||Franklin Genomic Advancements ETF||10.69|
|IDNA||C||iShares Genomics Immunology and Healthcare ETF||7.73|
|ARKG||D||ARK Genomic Revolution Multi-Sector ETF||5.82|
|ARKK||D||ARK Innovation ETF||5.27|
View all Genome Editing related ETFs...
|2021-04-22||ABEO||Crossed Above 20 DMA||Bullish|
|2021-04-22||ABEO||MACD Bullish Signal Line Cross||Bullish|
|2021-04-22||ABEO||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup|
|2021-04-22||ABEO||Pocket Pivot||Bullish Swing Setup|
|2021-04-22||CRSP||50 DMA Resistance||Bearish|
|2021-04-22||CRSP||Pocket Pivot||Bullish Swing Setup|
|2021-04-22||CRSP||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup|
|2021-04-22||CRSP||Bollinger Band Squeeze||Range Contraction|
|2021-04-22||DTIL||200 DMA Support||Bullish|
|2021-04-22||DTIL||20 DMA Resistance||Bearish|
|2021-04-22||EDIT||Calm After Storm||Range Contraction|
|2021-04-22||EDIT||Lower Bollinger Band Walk||Weakness|
|2021-04-22||NTLA||Crossed Above 20 DMA||Bullish|
Genome editing, or genome engineering, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits').
As of 2015 four families of engineered nucleases were used: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system. Nine genome editors were available as of 2017.Genome editing with engineered nucleases, i.e. all three major classes of these enzymes—zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and engineered meganucleases—were selected by Nature Methods as the 2011 Method of the Year. The CRISPR-Cas system was selected by Science as 2015 Breakthrough of the Year.